Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  alemtuzumab
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 28 for your search:
Start Over
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Phase: Phase III
Type: Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: DSHNHL 2006-1B / ACT-2, BMBF GFVT 01014715, NCT00725231
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: CCI #07-00119, CHLA-#07-00119, NCT00730314
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RHM CAN0638, 2008-007043-14, NCT01422603
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2012-0501, NCI-2013-01666, NCT01875237
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: AAAK8060, NCT02061800
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 to 80
Sponsor: NCI, NHLBI
Protocol IDs: 140077, 14-H-0077, NCT02105766
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: MF/SS, NCT00157274
Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: NHLBI
Protocol IDs: 060190, 06-H-0190, NHLBI-06-H-0190, NCT00345345
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: H-8701-MOHEL, MOHEL, NCT00368355
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
Phase: Phase II
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: NCI, Other
Protocol IDs: 2007.00, NCI-2009-01550, P30CA015704, FHCRC-2007.00, 6301, NCT00553098
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: BIO 07-122, NCT00618969
Study of Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) to Treat Hematologic Malignancies and Hematopoietic Failure States
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 09-0679-04, NCT00997386
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 100011, 10-C-0011, NCT01030900
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: L 10,321, NYMC 525, NCT01049854
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
Phase: Phase II
Type: Supportive care
Status: Active
Age: 16 to 70
Sponsor: Other
Protocol IDs: UHN REB 07-0436C, NCT00775632
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: Other
Protocol IDs: UCL/10/0241, LRF-09041, EU-21081, CRUK-UCL-PROT4, ProT4 (UCL/10/0241), PROT4, CRUK-UCL-10/0241, NCT01240525
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 10H06, NCI-2011-00514, STU00044115, NCT01361711
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-304, NCCN Protocol Number: NCCN-001, GSK Protocol Number: OFT115580, NCT01465334
Reduced Intensity Conditioning in Patients Aged =35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 months to 30 years
Sponsor: Other
Protocol IDs: RIC for HSCT in NMD, PRO13100018, NCT01962415
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMAB004, NCT01982175
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 months to 45 years
Sponsor: NCI, Other
Protocol IDs: BMTCTN1204, 2U10HL069294-11, NCT01998633
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NHLBI
Protocol IDs: 020250, 02-H-0250, NHLBI-02-H-0250, NCT00047060
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: RADIANT, NCI-2012-00588, NCT01625351
Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant
Phase: Phase I
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00003975, NCT01627275
Start Over